FDA warns of MS increases risk of stroke

The US Food and Drug Administration (FDA) has issued a new warning regarding the "Mitrada" multi-medical drug containing the active ingredient (altimozumab) after patients would have suffered a stroke and wall problems arteries of the head and neck.

The FDA noted that most patients with these symptoms had symptoms within one day after the initial administration of the drug "Lamtrada" and that, in one patient, the symptoms occurred three days after receiving the drug.

"The information is important for people with MS, but that does not mean that they should stop taking it immediately," said a specialist in MS.

"You always have to balance the risks and benefits of treatment with the risk of the disease," said Dr. Assaf Harel, a neurologist at Lenox Hill Hospital in New York. "For many patients, the drug is a truly effective treatment, The benefits can outweigh the potential risks for some patients.

In the interim, the Food and Drug Administration announced the imposition of a new warning regarding the risks badociated with the prescription drug information and patient treatment guide.